Methods for treating Parkinson's disease by administering resiniferatoxin
There is disclosed a method for treating Parkinson's Disease (PD) comprising administering an effective amount of Resiniferatoxin (RTX) by an intrathecal or intracisternal administration. In some embodiments, the dose of RTX for an adult human is from about 0.1 μg to about 100 μg.
1. A method for treating Parkinson's Disease (PD) comprising administering to a subject in need of treatment for PD an effective amount of Resiniferatoxin (RTX) intrathecally or intracisternally.
2. The method of claim 1 , wherein the subject is an adult human.
3. The method of claim 1 , wherein the RTX is administered in a dose of from about 0.1 μg to about 100 μg.
4. The method of claim 3 , wherein the dose is from about 0.1 μg to about 1 μg, about 1 μg to about 5 μg, about 5 μg to about 10 μg, about 10 μg, to about 20 μg, about 20 μg to about 50 μg, or about 50 to about 100 μg.
5. The method of claim 1 , wherein the method comprises intrathecal administration.
6. The method of claim 1 , wherein the method comprises intracisternal administration.
7. The method of claim 1 , wherein the RTX is administered in a pharmaceutical formulation comprising the RTX and a pharmaceutically acceptable carrier.
8. The method of claim 7 , wherein the pharmaceutically acceptable carrier comprises water.
9. The method of claim 7 , wherein the pharmaceutically acceptable carrier comprises saline.
10. The method of claim 7 , wherein the RTX is present in the pharmaceutical formulation at a concentration ranging from 1 μg/ml to 100 μg/ml.
11. The method of claim 10 , wherein the RTX is present in the pharmaceutical formulation at a concentration ranging from 1 μg/ml to 5 μg/ml, 5 μg/ml to 10 μg/ml, 10 μg/ml to 20 μg/ml, 20 μg/ml to 50 μg/ml, or 50 μg/ml to 100 μg/ml.